Evinacumab-dgnb Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Evinacumab-dgnb Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
14
Registered trials
11
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Evinacumab-dgnb can convert its Monoclonal antibody profile and ANGPTL3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Evinacumab-dgnb (query alias: evinacumab) |
|---|---|
| Modality / target | Monoclonal antibody; ANGPTL3; ANGPTL3 inhibitors |
| Highest global status | Approved |
| Originator | Regeneron Pharmaceuticals, Inc. |
| Active developers | Ultragenyx Germany GmbH, Ultragenyx Japan KK, Ultragenyx Pharmaceutical, Inc. |
The MCP disease footprint includes Homozygous familial hypercholesterolemia, Diabetic Nephropathies. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-jRCT2051220184 | Phase 3 | Complete | 11 | The incidence and severity of adverse eventsoccurring under the investigational treatment observed during the open-label period in patients treated with IV evinacumab 15 mg/kg every 4 weeks, as well as other safety endpoints. |
| NCT05611528 | Phase 3 | Completed | 10 | Change in lipid profile |
| NCT07271186 | Phase 2 | Recruiting | 270 | Percent change in Urine Albumin to Creatinine Ratio (UACR) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study
Phase 3; n=7; evaluation: Positive. Reported fields: Adverse Event: treatment-related adverse events = no treatment-related adverse events reported
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
Phase 2; n=21; evaluation: not stated. Reported fields: Percentage of Participants With at Least One Positively Adjudicated Acute Pancreatitis (AP) Episode = 10.0 Percentage of Participants ; Percentage of Participants With at Least One Positively Adjudicated Acute Pancreatitis (AP) Episode = 27.3 Percentage of Participants ; -
Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia
Phase 3; n=14; evaluation: Positive. Reported fields: AE = 71.4 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Evinacumab-dgnb addresses Homozygous familial hypercholesterolemia, Diabetic Nephropathies. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-01-07 | Ultragenyx will develop and market Regeneron's Evkeeza for the treatment of HoFH in the European Economic Area, excluding the United States. | Approved | US$30.0M upfront; US$63.0M milestones; US$93.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (SLC5a2) inhibitors”. The milestone feed surfaced a patent-application signal described as “Treatment of kidney disease with angiopoietin-like 3 (ANGPTL3) inhibitors”. The milestone feed surfaced a patent-application signal described as “Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
